Table I.
Substance | ALS cases per substance |
---|---|
Adalimumab | 13–18 |
Etanercept | 25–31 |
Infliximab | 20–24 |
Other RA-indicated chemical substance | ≤ 3 |
Other RA-indicated biological substance | ≤ 2 |
Other biological substance | ≤ 5 |
Substance | ALS cases per substance |
---|---|
Adalimumab | 13–18 |
Etanercept | 25–31 |
Infliximab | 20–24 |
Other RA-indicated chemical substance | ≤ 3 |
Other RA-indicated biological substance | ≤ 2 |
Other biological substance | ≤ 5 |